MUROMACHI CHEMICALS INC. Logo

MUROMACHI CHEMICALS INC.

A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.

4885 | T

Overview

Corporate Details

ISIN(s):
JP3914800002
LEI:
Country:
Japan
Address:
大牟田市新勝立町一丁目38番5
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Muromachi Chemicals Inc. is a diversified manufacturer operating across four core business segments. The Pharmaceutical division produces and sells medical products and active pharmaceutical ingredients (APIs). The Chemical business specializes in high-performance, customized liquid treatment systems for various applications, including environmental solutions. The Consumer Healthcare division manufactures and markets health foods. Additionally, the Functional Materials segment supports customer development with a broad range of standard and custom-made products for diverse markets. Founded in 1917, the company leverages its long-standing expertise to develop and provide innovative solutions that contribute to health and society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 03:41
Registration Form
確認書
Japanese 8.7 KB
2025-08-26 03:40
Registration Form
有価証券報告書-第79期(2024/06/01-2025/05/31)
Japanese 1020.4 KB
2025-01-14 08:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-01-14 08:00
Interim Report
半期報告書-第79期(2024/06/01-2025/05/31)
Japanese 214.1 KB
2024-09-04 03:00
Post-Annual General Meeting Information
臨時報告書
Japanese 27.6 KB
2024-08-28 08:34
Governance Information
内部統制報告書-第78期(2023/06/01-2024/05/31)
Japanese 22.8 KB
2024-08-28 08:32
Registration Form
有価証券報告書-第78期(2023/06/01-2024/05/31)
Japanese 986.7 KB
2024-08-28 08:32
Registration Form
確認書
Japanese 8.7 KB
2024-04-12 09:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-04-12 09:01
Quarterly Report
四半期報告書-第78期第3四半期(2023/12/01-2024/02/29)
Japanese 178.7 KB
2024-01-12 08:02
Quarterly Report
四半期報告書-第78期第2四半期(2023/09/01-2023/11/30)
Japanese 213.9 KB
2024-01-12 08:02
Report Publication Announcement
確認書
Japanese 8.7 KB
2023-10-13 09:02
Registration Form
確認書
Japanese 8.7 KB
2023-10-13 09:01
Quarterly Report
四半期報告書-第78期第1四半期(2023/06/01-2023/08/31)
Japanese 182.3 KB
2023-08-29 03:35
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB

Automate Your Workflow. Get a real-time feed of all MUROMACHI CHEMICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MUROMACHI CHEMICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MUROMACHI CHEMICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.